Marktanalyse - OTC Pharmaceuticals - Scandinavia Industry Guide

OTC Pharmaceuticals - Scandinavia Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry in each of the Scandinavian (Denmark, Norway and Sweden) countries. The report includes easily comparable data on market value, segmentation, and five forces analysis, plus full five year market forecasts for each country. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary market values, and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Denmark, Norway and Sweden, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

The Scandinavian food retail market had a total market value of $82.6 million in 2011.

Norway was the fastest growing country with a CAGR of 3.8% over the 2007—11 period.

Within the OTC pharmaceuticals industry, Sweden is the leading country among the Scandinavian countries, with market revenues of $494.1 million in 2010.

Sweden is expected to lead the OTC Pharmaceuticals in the scandinavian countries, with a value of $583.9 million in 2015.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The over-the-counter (OTC) pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin and other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2010 annual average exchange rates.

TABLE OF CONTENTS

Introduction 9

What is this report about? 9

Who is the target reader? 9

How to use this report 9

Definitions 9

Scandinavia OTC pharmaceuticals Industry Outlook 10

Market Analysis 10

Market Revenues 11

OTC pharmaceuticals in Denmark 15

Market Overview 15

Market Data 16

Market Segmentation 17

Market Outlook 22

Five Forces Analysis 23

Leading Companies 29

Macroeconomic Indicators 39

OTC pharmaceuticals in Norway 41

Market Overview 41

Market Data 42

Market Segmentation 43

Market Outlook 48

Five Forces Analysis 49

Leading Companies 55

Macroeconomic Indicators 63

OTC pharmaceuticals in Sweden 65

Market Overview 65

Market Data 66

Market Segmentation 67

Market Outlook 72

Five Forces Analysis 73

Leading Companies 79

Macroeconomic Indicators 89

Appendix 91

Methodology 91



LIST OF TABLES

Table 1: Scandinavia OTC pharmaceuticals industry, revenue ($m), 2006—15 11

Table 2: Scandinavia OTC pharmaceuticals industry, revenue ($m), 2006—10 12

Table 3: Scandinavia OTC pharmaceuticals industry forecast, revenue ($m), 2010—15 13

Table 4: Denmark OTC pharmaceuticals market value: $ million, 2006—10 16

Table 5: Denmark OTC pharmaceuticals market category segmentation : % share, by value, 2006 - 2010 17

Table 6: Denmark OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010 17

Table 7: Denmark OTC pharmaceuticals market geography segmentation, by value, 2010 19

Table 8: Denmark OTC pharmaceuticals market share: % share, by value, 2010 20

Table 9: Denmark OTC pharmaceuticals market distribution: % share, by value, 2010 21

Table 10: Denmark OTC pharmaceuticals market value forecast: $ million, 2010—15 22

Table 11: Johnson & Johnson: key facts 29

Table 12: Johnson & Johnson: key financials ($) 31

Table 13: Johnson & Johnson: key financial ratios 31

Table 14: Novartis AG: key facts 33

Table 15: Novartis AG: key financials ($) 34

Table 16: Novartis AG: key financial ratios 34

Table 17: GlaxoSmithKline Plc.: key facts 36

Table 18: GlaxoSmithKline Plc.: key financials ($) 37

Table 19: GlaxoSmithKline Plc.: key financials (£) 37

Table 20: GlaxoSmithKline Plc.: key financial ratios 37

Table 21: Denmark size of population (million), 2006—10 39

Table 22: Denmark GDP (constant 2000 prices, $ billion), 2006—10 39

Table 23: Denmark GDP (current prices, $ billion), 2006—10 39

Table 24: Denmark inflation, 2006—10 40

Table 25: Denmark consumer price index (absolute), 2006—10 40

Table 26: Denmark exchange rate, 2006—10 40

Table 27: Norway OTC pharmaceuticals market value: $ million, 2006—10 42

Table 28: Norway OTC pharmaceuticals market category segmentation : % share, by value, 2006 - 2010 43

Table 29: Norway OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010 43

Table 30: Norway OTC pharmaceuticals market geography segmentation, by value, 2010 45

Table 31: Norway OTC pharmaceuticals market share: % share, by value, 2010 46

Table 32: Norway OTC pharmaceuticals market distribution: % share, by value, 2010 47

Table 33: Norway OTC pharmaceuticals market value forecast: $ million, 2010—15 48

Table 34: Weifa AS: key facts 55

Table 35: Johnson & Johnson: key facts 56

Table 36: Johnson & Johnson: key financials ($) 58

Table 37: Johnson & Johnson: key financial ratios 58

Table 38: Novartis AG: key facts 60

Table 39: Novartis AG: key financials ($) 61

Table 40: Novartis AG: key financial ratios 61

Table 41: Norway size of population (million), 2006—10 63

Table 42: Norway GDP (constant 2000 prices, $ billion), 2006—10 63

Table 43: Norway GDP (current prices, $ billion), 2006—10 63

Table 44: Norway inflation, 2006—10 64

Table 45: Norway consumer price index (absolute), 2006—10 64

Table 46: Norway exchange rate, 2006—10 64

Table 47: Sweden OTC pharmaceuticals market value: $ million, 2006—10 66

Table 48: Sweden OTC pharmaceuticals market category segmentation : % share, by value, 2006 - 2010 67

Table 49: Sweden OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010 67

Table 50: Sweden OTC pharmaceuticals market geography segmentation, by value, 2010 69

Table 51: Sweden OTC pharmaceuticals market share: % share, by value, 2010 70

Table 52: Sweden OTC pharmaceuticals market distribution: % share, by value, 2010 71

Table 53: Sweden OTC pharmaceuticals market value forecast: $ million, 2010—15 72

Table 54: Johnson & Johnson: key facts 79

Table 55: Johnson & Johnson: key financials ($) 81

Table 56: Johnson & Johnson: key financial ratios 81

Table 57: GlaxoSmithKline Plc.: key facts 83

Table 58: GlaxoSmithKline Plc.: key financials ($) 84

Table 59: GlaxoSmithKline Plc.: key financials (£) 84

Table 60: GlaxoSmithKline Plc.: key financial ratios 84

Table 61: Novartis AG: key facts 86

Table 62: Novartis AG: key financials ($) 87

Table 63: Novartis AG: key financial ratios 87

Table 64: Sweden size of population (million), 2006—10 89

Table 65: Sweden GDP (constant 2000 prices, $ billion), 2006—10 89

Table 66: Sweden GDP (current prices, $ billion), 2006—10 89

Table 67: Sweden inflation, 2006—10 90

Table 68: Sweden consumer price index (absolute), 2006—10 90

Table 69: Sweden exchange rate, 2006—10 90



LIST OF FIGURES

Figure 1: Scandinavia OTC pharmaceuticals industry, revenue ($m), 2006—15 11

Figure 2: Scandinavia OTC pharmaceuticals industry, revenue ($m), 2006—10 12

Figure 3: Scandinavia OTC pharmaceuticals industry forecast, revenue ($m), 2010—15 13

Figure 4: Scandinavia OTC pharmaceuticals industry, Segmentation (%), 2010 14

Figure 5: Denmark OTC pharmaceuticals market value: $ million, 2006—10 16

Figure 6: Denmark OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010 18

Figure 7: Denmark OTC pharmaceuticals market geography segmentation : % share, by value, 2010 19

Figure 8: Denmark OTC pharmaceuticals market share: % share, by value, 2010 20

Figure 9: Denmark OTC pharmaceuticals market distribution: % share, by value, 2010 21

Figure 10: Denmark OTC pharmaceuticals market value forecast: $ million, 2010—15 22

Figure 11: Forces driving competition in the OTC pharmaceuticals market in Denmark, 2010 23

Figure 12: Drivers of buyer power in the OTC pharmaceuticals market in Denmark, 2010 24

Figure 13: Drivers of supplier power in the OTC pharmaceuticals market in Denmark, 2010 25

Figure 14: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Denmark, 2010 26

Figure 15: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Denmark, 2010 27

Figure 16: Drivers of degree of rivalry in the OTC pharmaceuticals market in Denmark, 2010 28

Figure 17: Johnson & Johnson: revenues & profitability 32

Figure 18: Johnson & Johnson: assets & liabilities 32

Figure 19: Novartis AG: revenues & profitability 35

Figure 20: Novartis AG: assets & liabilities 35

Figure 21: GlaxoSmithKline Plc.: revenues & profitability 38

Figure 22: GlaxoSmithKline Plc.: assets & liabilities 38

Figure 23: Norway OTC pharmaceuticals market value: $ million, 2006—10 42

Figure 24: Norway OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010 44

Figure 25: Norway OTC pharmaceuticals market geography segmentation : % share, by value, 2010 45

Figure 26: Norway OTC pharmaceuticals market share: % share, by value, 2010 46

Figure 27: Norway OTC pharmaceuticals market distribution: % share, by value, 2010 47

Figure 28: Norway OTC pharmaceuticals market value forecast: $ million, 2010—15 48

Figure 29: Forces driving competition in the OTC pharmaceuticals market in Norway, 2010 49

Figure 30: Drivers of buyer power in the OTC pharmaceuticals market in Norway, 2010 50

Figure 31: Drivers of supplier power in the OTC pharmaceuticals market in Norway, 2010 51

Figure 32: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Norway, 2010 52

Figure 33: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Norway, 2010 53

Figure 34: Drivers of degree of rivalry in the OTC pharmaceuticals market in Norway, 2010 54

Figure 35: Johnson & Johnson: revenues & profitability 59

Figure 36: Johnson & Johnson: assets & liabilities 59

Figure 37: Novartis AG: revenues & profitability 62

Figure 38: Novartis AG: assets & liabilities 62

Figure 39: Sweden OTC pharmaceuticals market value: $ million, 2006—10 66

Figure 40: Sweden OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010 68

Figure 41: Sweden OTC pharmaceuticals market geography segmentation : % share, by value, 2010 69

Figure 42: Sweden OTC pharmaceuticals market share: % share, by value, 2010 70

Figure 43: Sweden OTC pharmaceuticals market distribution: % share, by value, 2010 71

Figure 44: Sweden OTC pharmaceuticals market value forecast: $ million, 2010—15 72

Figure 45: Forces driving competition in the OTC pharmaceuticals market in Sweden, 2010 73

Figure 46: Drivers of buyer power in the OTC pharmaceuticals market in Sweden, 2010 74

Figure 47: Drivers of supplier power in the OTC pharmaceuticals market in Sweden, 2010 75

Figure 48: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Sweden, 2010 76

Figure 49: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Sweden, 2010 77

Figure 50: Drivers of degree of rivalry in the OTC pharmaceuticals market in Sweden, 2010 78

Figure 51: Johnson & Johnson: revenues & profitability 81

Figure 52: Johnson & Johnson: assets & liabilities 82

Figure 53: GlaxoSmithKline Plc.: revenues & profitability 85

Figure 54: GlaxoSmithKline Plc.: assets & liabilities 85

Figure 55: Novartis AG: revenues & profitability 88

Figure 56: Novartis AG: assets & liabilities 88

• OTC Triptans in Norway
• OTC Triptans in Azerbaijan
• OTC Triptans in Kazakhstan
• OTC Triptans in Sweden
• Calming and Sleeping in Australia
• Calming and Sleeping in Croatia
• Cough, Cold and Allergy (Hay Fever) Remedies in Australia
• Cough, Cold and Allergy (Hay Fever) Remedies in Croatia
• Over-the-counter Pharmaceuticals Market in the Asia Pacific Region 2012-2016
• Over-the-counter Pharmaceuticals Market in the Asia Pacific Region 2012-2016
• Global Over-the-counter Pharmaceutical Market 2012-2016
• OTC Pharmaceuticals and Self-medication in Seven Emerging Markets
• OTC Triptans in Germany
• OTC Triptans in Sweden
• OTC Triptans in the United Kingdom
• Cough, Cold and Allergy (Hay Fever) Remedies in the US
• Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
• Global OTC Pharmaceuticals
• OTC Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide
• OTC Pharmaceuticals - Global Group of Eight (G8) Industry Guide